David Larsen, an analyst from BTIG, maintained the Buy rating on BrightSpring Health Services, Inc.. The associated price target remains the same with $55.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
David Larsen has given his Buy rating due to a combination of factors that highlight BrightSpring’s strong positioning and growth outlook. He views BTSG as a leading, high‑quality operator that is gaining market share, supported by robust utilization trends, solid referral relationships, and payors’ push toward lower‑cost post‑acute care settings, all of which are driving healthy volume and earnings expansion.
Larsen also emphasizes the strong momentum in the Pharmacy and Provider segments, with double‑digit revenue growth translating into outsized EBITDA gains, even after accounting for IRA and brand‑to‑generic headwinds. He points to meaningful margin upside from specialty brand‑to‑generic conversions, steady provider reimbursement, improved leverage after the Community Living divestiture, and solid cash generation, and believes these strengths justify upside to the current valuation and support his $55 price target.
In another report released yesterday, Morgan Stanley also reiterated a Buy rating on the stock with a $48.00 price target.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BTSG in relation to earlier this year.